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ABSTRACT: We describe novel acetohydroxamic acid derivatives with potent activity against cultured bloodstream-form
Trypanosoma brucei and selectivity indices of >1000. These analogues were derived from conformationally constrained, lipophilic,
spiro carbocyclic 2,6-diketopiperazine (2,6-DKP) scaﬀolds by attaching acetohydroxamic acid moieties to the imidic nitrogen.
Optimalactivitywasachievedbyplacingbenzylgroupsadjacenttothebasicnitrogenofthe2,6-DKPcore.S-Enantiomer7dwasthe
most active derivative against T. brucei (IC50 = 6.8 nM) and T. cruzi (IC50 = 0.21 μM).
’INTRODUCTION
Human African trypanosomiasis is caused by tsetse ﬂy trans-
mitted parasites of the Trypanosoma brucei species complex.
Over 50 million people in sub-Saharan Africa are at risk.
1a,b
In 2009, there were 30000 cases,
1c although during epidemics,
this level can increase >10-fold.
1d Chagas disease (or American
trypanosomiasis) is caused by Trypanosoma cruzi and aﬀects
8 10 million people in Latin America, resulting in >15 000
deaths per year.
1a,b,2 Therapy for trypanosomal infections is
unsatisfactory because of toxic side eﬀects, the development
of resistance, and in many cases the need for parenteral
administration.
3 With no immediate prospect of vaccines, there
is a great need to develop new antitrypanosome agents with an
acceptable eﬃcacy and safety proﬁle.
Amantadine and rimantadine are anti-inﬂuenza A drugs that
inhibit virus replication at micromolar concentrations.
4 Blood-
stream-form T. brucei are sensitive in vitro to amantadine and
rimantadine, particularly the latter drug (IC50 =7μM).
5
Rimantadine also has activity against the trypanosomatid para-
sitesT.cruziandLeishmaniamajor.
5Itwassubsequentlyreported
that a series of aminoadamantane and aminoalkylcyclohexane
derivativeswereeﬀective ininhibitinggrowth ofT.bruceiinvitro
and in vivo and that inhibition was correlated with lipophilicity.
Some of these derivatives showed submicromolar trypanocidal
activities,
6themostpotentbeing1and2(Figure1).Recently,we
described the synthesis and trypanocidal properties of several
nitrogen-containing adamantane derivatives.
7,8 Of these, 3 5
(Figure1)wereactiveinvitroagainstT.brucei.Oxazolone3
8was
the most active, with a potency that was 3-fold higher than
rimantadine and at least 45-fold greater than amantadine.
To determine how structural features aﬀect the trypanocidal
activity of compounds based on adamantane or other lipophilic
carbocycles, we explored spiro 2,6-diketopiperazine derivatives
6a and 6b (Figure 1) (synthesis of 6a has been described by
us previously
9). A preliminary screen of 2,6-diketopiperazines
(2,6-DKPs) 6a and 6b (5 μgm L
 1) against bloodstream-form
T. brucei revealed that 2,6-DKP 6a was inactive while its N-4 methyl
counterpart 6b had only marginal eﬀects on parasite growth
(40% inhibition). Despite these results, we have continued to
investigatethelipophilicspirocarbocyclic2,6-DKPcorewiththe
view of improving antitrypanosome potency.
Several essential trypanosomatid metalloenzymes have been
identiﬁed, and their inhibition has been recognized as an app-
roach to chemotherapy.
10 17 The focus has been zinc or iron
metalloenzymes.
11 15,17
Hydroxamic acids form strong complexes with a range of
metals, especially iron.
18 This has been exploited to produce
inhibitors of metalloenzymes implicated in the pathophysiology
Figure 1. Structuresoflipophilicadamantaneaminoderivatives1 5
5 8
with activity against T. brucei, and structures of the 2,6-DKPs 6a and
6b and the new hydroxamic acid derivatives 7a e, 8, 9a d, 10a,
and 10b.
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of human diseases
19 21 (cancer, inﬂammatory conditions, etc).
Of particular interest are the zinc and iron metalloenzyme
hydroxamateinhibitorsandtheiruseasmatrixmetalloproteinase
(MMP),histonedeacetylase(HDAC),and5-lipoxygenase(5-LO)
inhibitors.
19 21 In all of the above cases, the hydroxamic acid
moietyisrequiredforinhibition,whichismediatedbybindingto
the metal ion in the catalytic site.
Studies on the trypanocidal activity of hydroxamic acid-based
derivatives have been limited. Hydroxamate analogues are selec-
tive inhibitors of T. brucei 6-phosphoglyconate dehydrogenase
(Tb6PGDH). They have a sugar-like backbone (hydroxamate
derivatives of 4-phospho-D-erythronic acid) and mimic the high-
energy intermediates of the 6PGDH enzymatic reaction.
22
Despite their potency and selectivity, these analogues were
devoid of signiﬁcant in vitro activity. Another compound of
interest is the alternative oxidase inhibitor salicylhydroxamic
acid, which has some trypanocidal activity, although this may
be due to the hydroxyl substituted benzoic acid moiety.
23
Inthiscurrentstudy,weusedlipophilic2,6-DKPs6aand6bas
conformationally constrained scaﬀold molecules onto which we
attached hydroxamate units as potential metal-chelating moieties.
We describe the synthesis of several derivatives (Figure 1) that
have potent trypanocidal activity while being relatively nontoxic
to mammalian cells.
’CHEMISTRY
As depicted in Scheme 1, carboxylic acids 27 31, 41, 56 59,
70,a n d71 were the key structures in preparing the new target
compounds. Thus, their coupling with O-benzylhydroxylamine in
Scheme 1
a
aReagents and conditions: (a) NaCN, appropriate R-amino acid alkyl ester hydrochloride, DMSO/H2O 29:1 (v/v), room temp, 48 h; (b) (i) H2SO4
97%,roomtemp,24hfor17,18,48orH2SO497%,CH2Cl2,roomtemp,48hfor19 21or24hfor49 51;(ii)iceandthenaqNH326%topH7 8;
(c) (i) (Me3Si)2NK (1 equiv), THF, 0 5 C, then room temp, 1 h, argon; (ii) BrCH2CO2CH2Ph or BrCH2CONH2 only for 43, DMF, room temp,
48h,argon,78 94%for22 26,52 54,62%for55from47,50%for43;(d)H2/Pd10%,EtOHfor27,28,41,56,57,59,70,71,7a e,8,9a d,10a,
10borEtOH/AcOEt3:2(v/v)for29 31,58,50psi,roomtemp,3h,>99%for27 31,56 59,41,70,71,80 95%for7a e,8,9a d,10a,10b;(e)
(i) CDI, THF for 32 36, 42, 45, 61, 62, 72, 73 or THF/DMF 3:4 for 60 or THF/DMF 4:1 for 63,2 8C, 1 h, argon; (ii) PhCH2ONH23HCl or
CH3ONH23HCl only for 45,E t 3N, 28 C, 25 h, argon for 33 35, 61, 62,o r2 8C, 24 h, then 45 C, 1 h, argon for 32, 36, 42, 45, 60, 63, 72, 73,
63 95%; (f) as (e) using H2NNHCO2CH2Ph, THF, 28 C, 25 h, then as (d), EtOH, 76%; (g) as (c) (i), then CF3CO2H (1 equiv), >99%; (h) (i) aq
CH2O37%,MeOH/THF1:1for6borMeOH/THF1:3for66,67,roomtemp,3h,thenNaCNBH3,roomtemp,4hatpH6 7(maintainedbyadding
AcOH); (ii)1NNaOHandNa2CO3to pH8,80 92%;(i) NaH,DMF,roomtemp,1h,argonandthenas(c)(ii)usingBrCH2CO2CH2Ph,83 95%.5252 dx.doi.org/10.1021/jm200217m |J. Med. Chem. 2011, 54, 5250–5254
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the presence of 1,10-carbonyldiimidazole (CDI) in THF led to the
corresponding O-benzyl hydroxamates 32 36, 42, 60 63, 72,
and73 in yields 63 95%. Accordingly, the O-methyl hydroxamate
analogue 45 was obtained by coupling the carboxylic acid 27 with
O-methylhydroxylamine. The acetohydroxamic acid analogues
7a e, 8, 9a d, 10a,a n d10b were acquired in high yields
(80 95%) upon hydrogenolysis of the respective O-benzylhydro-
xamate derivatives.Inasimilar manner, 27 wasreactedwithbenzyl
hydrazinecarboxylate to aﬀord, after removal of the protecting
group by hydrogenolysis, the acetohydrazide analogue 44.
The synthesis of the carboxylic acids 27, 28,a n d56,a n d
1-unsubstituted2,6-DKPs6aand64(Scheme1)hasbeendescribed
in our previously published protocol.
9 By employment of the same
methodology, their respective structural analogues 29 31, 57 59,
37 39,a n d65 were further synthesized as part of this study.
For the synthesis of the N-methylated carboxylic acids 41, 70,
and 71 (Scheme 1), the 2,6-DKPs 6a, 64, and 65 were subjected
to reductive methylation with CH2O/NaCNBH3 to give in
80 92%yieldsthemethylanalogues6b,66,and67,respectively.
The latter compounds, upon reaction with benzyl bromoacetate
inNaH/DMF,areconvertedtothecorrespondingN-methylated
2,6-DKP-1-acetic acid benzyl esters (40, 68, and 69)i n8 3  95%
yields. The carboxylic acids 41, 70, and 71 were aﬀorded in
almost quantitative yield by catalytic hydrogenolysis of their
respective benzyl esters.
The 1-functionalized acetamide analogue 43 (Scheme 1) was
prepared from 17 by the sequence of cyclization and functiona-
lization reactions described for the preparation of the benzyl
esters 22 26 except that bromoacetamide was used instead of
benzyl bromoacetate.
’RESULTS AND DISCUSSION
We introduced an acetohydroxamic acid group (CH2CONH-
OH) at the imidic nitrogen of the 2,6-DKPs 6a and 6b, with the
aim of achieving trypanocidal activity, potentially through in-
hibitionofanessentialmetalloenzyme.Thismodiﬁcationresulted
in 7a and 7b (Figure 1), which were synthesized and tested
against bloodstream-form T. brucei in vitro. They exhibited try-
panocidal activity in the nanomolar range [IC50(7a) = 90 nM;
IC50(7b)=193nM(Table1)],identifyingtheseacetohydroxamic
acid derivatives as promising lead compounds. We next gener-
ated derivatives in which the basic spiro carbocyclic 2,6-DKP-1-
acetohydroxamic structure was retained. First, we modiﬁed the
7a and 7b structures by replacement of the spiro adamantane
portion with less bulky and lipophilic spiro cyclooctanes or
cycloheptanes, resulting in the cycloalkane congeners 9a, 9b,
10a, and 10b. A further modiﬁcation involved incorporation of a
methyl or benzyl substituent at the position between the basic
nitrogen andcarbonyl groupinthespiroheterocyclicskeleton of
the parent compounds7aand 9a,leading tothealkyl substituted
hydroxamate analogues 7c e, 8, 9c, and 9d. These analogues
were tested against bloodstream-form T. brucei. 7a, 7b, and 7d
werealsotestedagainstT.cruziepimastigotes.TheresultingIC50
and IC90 are shown in Table 1.
The newly synthesized hydroxamic acid derivatives were
potently active against T. brucei in free base and hydrochloride
forms, with IC50 ranging from 6.8 to 1870 nM and from 9.2 to
1150 nM, respectively. Compounds 7d, 7e, 8, and 9d were the
most potent against African trypanosomes, with activity in the
low nanomolar range (IC50s = 6.8 29 nM, Table 1), while
hydroxamates7a,7b,and7dwerealsosigniﬁcantlyactiveagainst
T. cruzi epimastigotes. To assess the role of the hydroxamic acid
moiety in the activity of 7a e, 8, 9a d, 10a, and 10b,w e
replaced the acetohydroxamate pharmacophore of 7a with
related functional groups such as acetamide (CH2CONH2),
acetohydrazide (CH2CONHNH2), and O-methyl acetohydrox-
amate(CH2CONH-OCH3).Thesemodiﬁcationsresultedin43,
44,and45(Scheme1).Wealsoselectivelyassessedsomeoftheir
corresponding carboxylic acid precursors [27 31, 41, 56, 59,
Table 1. Activity of Acetohydroxamic Acid Analogues 7a e, 8, 9a d, 10a, and 10b (Figure 1) Tested against Cultured
Bloodstream-FormT.brucei(pH7.4)andT.cruziEpimastigotesandCytotoxicityoftheMostActiveCompoundsagainstCultured
Rat Skeletal Myoblast L6 Cells (Supporting Information)
activity
T. brucei T. cruzi cytotoxicity
compd IC50 (nM)
a,b IC90 (nM)
a,b IC50(μM)
a IC90 (μM)
a IC50 (μM)
c SI
d
7a 90 ( 16 (79 ( 6) 155 ( 7 (148 ( 8) 5.51 ( 0.68 11.11 ( 1.19 >325 >3600
7b 193 ( 28 (340 ( 28) 328 ( 28 (622 ( 84) 3.62 ( 0.31 5.99 ( 0.16 40.4 ( 5.6 210
7c 134 ( 33 (405 ( 98) 276 ( 12 (909 ( 209)
7d 6.8 ( 1.4 (42 ( 5) 11.5 ( 2 (80 ( 22) 0.21 ( 0.04 0.36 ( 0.01 10.4 ( 0.9 1500
7e 9.1 ( 0.2 (9.2 ( 0.5) 14 ( 1 (14 ( 1) 11.6 ( 1.5 1300
8 17 ( 1 (18 ( 1) 26 ( 3 (24 ( 1) 23.7 ( 0.4 1400
9a 300 ( 25 (266 ( 19) 635 ( 14 (495 ( 28)
9b 158 ( 34 (162 ( 15) 300 ( 34 (327 ( 9)
9c 125 ( 30 (134 ( 13) 270 ( 41 (259 ( 25)
9d 29 ( 3 (25 ( 2) 39 ( 1 (35 ( 1) 93.8 ( 18.8 3200
10a 1870 ( 80 (1150 ( 130) 2530 ( 290 (1710 ( 40)
10b 285 ( 9 (311 ( 7) 673 ( 56 (717 ( 113)
aConcentrations required to inhibit growth of T. brucei and T. cruzi by 50% and 90%, respectively. IC50 and IC90 data are the mean of triplicate
experiments ( SEM.
bIC50 and IC90 data for the respective hydrochloride are shown in parentheses.
cCytotoxicity was determined by establishing the
concentration required to inhibit growth of cultured L6 cells by 50% (IC50) (Supporting Information). Data are the mean of triplicate experiments
( SEM.
dSelectivity indices were calculated as the ratio of the IC50 for L6 cells to IC50 for T. brucei.5253 dx.doi.org/10.1021/jm200217m |J. Med. Chem. 2011, 54, 5250–5254
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and 71 (Scheme 1)] and some additional spiro carbocyclic 2,6-
DKP scaﬀold molecules [37 39 and 64 67 (Scheme 1)].
These modiﬁcations resulted in a substantial loss of activity
against bloodstream-form T. brucei (Table 2, Supporting In-
formation), suggesting that the hydroxamic acid unit is indispen-
sable for trypanocidal activity in this class of compounds.
Changing the adamantane component of structure 7a for a
cyclooctane (9a) or cycloheptane (10a) progressively decreased
activity against T. brucei (Table 1). Compared with 7a, the IC50
of cyclooctane 9a is 3.3-fold lower (IC50 = 300 nM), whereas the
cycloheptaneanalogue10ais21-foldlessactive(IC50=1870nM).
This marked loss of activity demonstrates the negative eﬀect of
reducing the bulkiness and lipophilicity of the carbocyclic ring
and identiﬁes the cycloheptane-based spiro 2,6-DKP core as a
less eﬀective scaﬀold for the acetohydroxamate pharmacophore.
Introduction of a methyl substituent on the basic nitrogen
atom of the respective spiro carbocyclic 2,6-DKP residue of the
parent compounds 7a, 9a, and 10a (N-methylation) led to a 2.1-
fold decrease in potency for the N-methyladamantane analogue
7b, while enhanced activity was observed in the cases of the
cyclooctane and cycloheptane N-methyl counterparts 9b and
10b. They were 1.9 and 6.6 times more potent than the
corresponding NH-analogues 9a and 10a (Table 1). A similar
trendwasobservedwhenthemethylsubstituentwasincorporated
intothemethylenecarbon adjacent tothebasicnitrogenatomof
the 2,6-DKP ring (C-methylation) in 7a and 9a, resulting in the
respective C-methyl analogues 7c and 9c with S-conﬁguration of
the created chiral carbon. Thus, 7c was 1.5 times less active than
7a, whereas 9c was 2.4-fold more eﬀective than 9a (Table 1).
Therefore, N-o rC-methyl substitution on 2,6-DKP ring seems
to enhance trypanocidal activity only in the context of the
cyclooctane- or cycloheptane-containing acetohydroxamic acid
analogues (9b, 9c, and 10b).
Theadditionofthebulkyhydrophobicbenzylsubstituenttothe
same carbon of the adamantane parent 7a yielded analogues that
were unexpectedly potent against T. brucei,a se x e m p l i ﬁed by 7d
(S-enantiomer), 7e (R-enantiomer), and 8 (racemic mixture)
(Table 1). Enantiomers 7d and 7e and their racemic mixture 8
retained high potency, although the S-enantiomer was slightly
moreactive[7d(IC50=6.8nM);7e(IC50=9.1nM);8(IC50=17
nM)]. Their activities in the free base form were 5.3 13 times
higher than the parent 7a and 8 20 times higher than their
C-methyl analogue 7c. A similar eﬀect was observed when an
analogousbenzylsubstitutionwasmadetothecyclooctaneparent
9a, leading to 9d (S-enantiomer). This derivative had 10 times
more trypanocidal activity than 9a and 4.3 times more than its C-
methylcounterpart9c(Table1).Thislargeincreaseinpotencyfor
7d, 7e, 8,a n d9d must reﬂect the strongly favorable stereoelec-
tronicandlipophiliceﬀectsexertedbythebenzylsubstituentinthe
binding site. The most potent derivatives (7d, 7e, 8)w e r ea l s o
tested against cultured procyclic (insect form) T. brucei. These
were found to be 10 50 times more resistant to the trypanocidal
eﬀects [7d (IC50 =3 3 2( 25 nM); 7e (IC50 =1 0 6( 6n M ) ;8
(IC50=285(20nM)].Thisimpliesthatthemajortargetofthese
compounds may be less important in procyclics.
Some diﬀerences in activity against bloodstream-form T. brucei
were detected between the free base and hydrochloride forms
offourofthetargetcompounds:7b dand10a(Table1).For
7b, 7c,and7d,theirhydrochloridesdisplayed1.8-,3-,and6.2-
foldlowerpotency,respectively.Incontrast,10a3HClwas1.6
times more potent than the corresponding free base. Interest-
ingly, the order of activity obtained with 7d, 7e, and 8 was
diﬀerent when tested as hydrochloride salts. 7d (S-enantiomer)
was lesspotentthan7e(R-enantiomer)and8(racemic mixture)
byafactorof4.6and2.3, respectively[7e3HCl(IC50=9.2nM);
83HCl (IC50 = 18 nM); 7d3HCl (IC50 = 42 nM)]. The reason
for this is unknown.
Adamantane-based7a,7b,and7dinfreebaseformalsoprovedto
besigniﬁcantlyactiveagainstculturedT.cruziepimastigotes,withan
IC50 at low micromolar to submicromolar levels (0.21 5.51 μM)
(Table 1). Interestingly, the pattern of activity of the N-methyl
analogue 7b was opposite that shown by T. brucei.I tw a s1 . 5 - f o l d
more potent against T. cruzi than the parent structure 7a.A sw i t hT.
brucei, C-benzyl substitution on 7a,l e a d i n gt o7d,s i g n i ﬁcantly
improved activity against T. cruzi, providing a 26-fold increase
relativeto7a.Thecytotoxicityofthemostactivecompoundsagainst
mammalian cells was determined using the rat skeletal myoblast L6
cell line. These experiments showed that derivatives 7b, 7d, 7e, 8,
and9dhadIC50inthe10 100μMrangeandthatmammaliancells
were largely refractory to the eﬀects of 7a (Table 1). The resulting
selectivity indices, which varied from 210 (7b) to >3600 (7a), were
highly promising in terms of drug development.
The excellent trypanocidal activity obtained with the hydro-
xamate analogues 7a e, 8, 9a d, 10a, and 10b demonstrates
that lipophilic spiro carbocyclic 2,6-DKP scaﬀolds constitute
valuable platforms for developing antitrypanosome agents,
throughanacetohydroxamatesubstitutionontheirimidicnitrogen.
Coupling of these well-deﬁned chemical entities results in strongly
enhanced activity through synergism of their structural features.
The corresponding scaﬀold molecules are substantially inactive
[6a, 6b, and 64 67, Table 2 (Supporting Information)] or only
slightlyactive (37 39,Table 2),andacetohydroxamic aciditself
has little trypanocidal eﬀect (IC50 = 680 μM, Table 2).
Replacement of the hydroxamic acid group greatly diminishes
trypanocidal properties (Table 2), suggesting that this com-
ponent is a requirement for activity. One possibility is that this
classofcompoundactsbyinhibitingavitalparasitemetalloenzyme,
through the metal ion binding action of this moiety. Within this
mechanism, the structural features of the spiro heterocyclic
scaﬀold would be required for high-aﬃnity interactions, includ-
ing hydrogen bonds and electrostatic and hydrophobic interac-
tions. Additional studies are required to understand the exact
mechanism of action of these acetohydroxamic acid-based try-
panocidal agents and to identify their target within the parasite.
’CONCLUSION
We have successfully transformed lipophilic spiro carbocyclic
2,6-DKP scaﬀolds into compounds that are active against T. brucei
and T. cruzi by incorporating an acetohydroxamic acid moiety into
theirimidicnitrogenatom.Thiscouldactasametalioncomplexing
functional group. Compounds 7d, 7e, and 8 show low nano-
molar trypanocidal activity against bloodstream-form T. brucei,
and 7a, 7b, and 7d display signiﬁcant activity against T. cruzi.
Compound 7d, based on scaﬀold molecule (S)-6-benzyl-3,5-
dioxospiro[piperazine-2,20-adamantane](37),wasthemostactive
derivative against T. brucei and T. cruzi with IC50 of 6.8 nM and
0.21 μM, respectively. Importantly, these compounds had very
favorable selectivity indices when their activities against trypano-
somes and mammalian cells were compared. Because of their
potent antitrypanosome eﬀect, the novel spiro carbocyclic 2,6-
DKP-1-acetohydroxamic acids represent lead structures for the
development of new treatments against African and American
trypanosomiasis.5254 dx.doi.org/10.1021/jm200217m |J. Med. Chem. 2011, 54, 5250–5254
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’EXPERIMENTAL SECTION: CHEMISTRY
General. The purities of the tested compounds were determined by
elemental analysis. The results obtained correspond to >95% purity
(Supporting Information, Table 3).
GeneralProcedureforthePreparationoftheHydroxamic
Acids 7a e, 8, 9a d, 10a, and 10b. A solution of the appropriate
O-benzyl hydroxamate (1 mmol) in absolute EtOH (40 mL) was
hydrogenated (Pd C 10%, 45 mg) for 3 h at room temperature and
50psi.Thecatalystwasfilteredoff,washedwithEtOH(3 10mL),and
the combined filtrates were evaporated in vacuo. Purification of the
residue by column chromatography on silica gel using AcOEt MeOH
5:1(7a,7b,9a)orAcOEt(7c e,8,9b d,10a,10b)providedthepure
hydroxamic acid as a white crystalline or foamy solid (Supporting
Information).
’ASSOCIATED CONTENT
b S Supporting Information. Synthesis details of 7a e, 8,
9a d,10a,10b,43 45,14,19,24,29,32,37,6b,40,41,66,68,
and 70; chemical and physical data; antitrypanosomeactiondata
of 43 45, 27 31, 41, 56, 59, 71, 6a, 6b, 37 39, and 64 67;
biological assays; elemental analysis data of the tested com-
pounds.ThismaterialisavailablefreeofchargeviatheInternetat
http://pubs.acs.org.
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